NZ604040A - The use of inhibitors of bruton’s tyrosine kinase (btk) - Google Patents

The use of inhibitors of bruton’s tyrosine kinase (btk)

Info

Publication number
NZ604040A
NZ604040A NZ604040A NZ60404011A NZ604040A NZ 604040 A NZ604040 A NZ 604040A NZ 604040 A NZ604040 A NZ 604040A NZ 60404011 A NZ60404011 A NZ 60404011A NZ 604040 A NZ604040 A NZ 604040A
Authority
NZ
New Zealand
Prior art keywords
medicament
rituximab
cyclophosphamide
bruton
btk
Prior art date
Application number
NZ604040A
Other languages
English (en)
Inventor
Eric Hedrick
Tarak D Mody
Joseph J Buggy
David J Loury
Laurence Elias
Gwen Fyfe
Original Assignee
Pharmacyclics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45067334&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ604040(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacyclics Inc filed Critical Pharmacyclics Inc
Priority to NZ702485A priority Critical patent/NZ702485A/en
Publication of NZ604040A publication Critical patent/NZ604040A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NZ604040A 2010-06-03 2011-06-03 The use of inhibitors of bruton’s tyrosine kinase (btk) NZ604040A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ702485A NZ702485A (en) 2010-06-03 2011-06-03 The use of inhibitors of bruton’s tyrosine kinase (btk)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US35113010P 2010-06-03 2010-06-03
US35165510P 2010-06-04 2010-06-04
US35176210P 2010-06-04 2010-06-04
US35179310P 2010-06-04 2010-06-04
US41976410P 2010-12-03 2010-12-03
US201161472138P 2011-04-05 2011-04-05
PCT/US2011/039190 WO2011153514A2 (en) 2010-06-03 2011-06-03 The use of inhibitors of bruton's tyrosine kinase (btk)

Publications (1)

Publication Number Publication Date
NZ604040A true NZ604040A (en) 2015-02-27

Family

ID=45067334

Family Applications (7)

Application Number Title Priority Date Filing Date
NZ604040A NZ604040A (en) 2010-06-03 2011-06-03 The use of inhibitors of bruton’s tyrosine kinase (btk)
NZ772688A NZ772688A (en) 2010-06-03 2011-06-03 The use of inhibitors of bruton’s tyrosine kinase (btk)
NZ717373A NZ717373A (en) 2010-06-03 2011-06-03 The use of inhibitors of bruton’s tyrosine kinase (btk)
NZ73604811A NZ736048A (en) 2010-06-03 2011-06-03 The use of inhibitors of bruton’s tyrosine kinase (btk)
NZ753024A NZ753024A (en) 2010-06-03 2011-06-03 The use of inhibitors of bruton’s tyrosine kinase (btk)
NZ702485A NZ702485A (en) 2010-06-03 2011-06-03 The use of inhibitors of bruton’s tyrosine kinase (btk)
NZ789041A NZ789041A (en) 2010-06-03 2011-06-03 The use of inhibitors of bruton’s tyrosine kinase (btk)

Family Applications After (6)

Application Number Title Priority Date Filing Date
NZ772688A NZ772688A (en) 2010-06-03 2011-06-03 The use of inhibitors of bruton’s tyrosine kinase (btk)
NZ717373A NZ717373A (en) 2010-06-03 2011-06-03 The use of inhibitors of bruton’s tyrosine kinase (btk)
NZ73604811A NZ736048A (en) 2010-06-03 2011-06-03 The use of inhibitors of bruton’s tyrosine kinase (btk)
NZ753024A NZ753024A (en) 2010-06-03 2011-06-03 The use of inhibitors of bruton’s tyrosine kinase (btk)
NZ702485A NZ702485A (en) 2010-06-03 2011-06-03 The use of inhibitors of bruton’s tyrosine kinase (btk)
NZ789041A NZ789041A (en) 2010-06-03 2011-06-03 The use of inhibitors of bruton’s tyrosine kinase (btk)

Country Status (18)

Country Link
US (24) US20120087915A1 (enExample)
EP (1) EP2575818A4 (enExample)
JP (8) JP5841998B2 (enExample)
KR (1) KR101580714B1 (enExample)
CN (2) CN107898791A (enExample)
AU (1) AU2011261185A1 (enExample)
BR (1) BR112012030625A2 (enExample)
CA (7) CA2800913C (enExample)
CL (1) CL2012003381A1 (enExample)
EA (2) EA031737B1 (enExample)
IL (3) IL300955A (enExample)
MX (4) MX342405B (enExample)
MY (1) MY191929A (enExample)
NZ (7) NZ604040A (enExample)
PH (3) PH12012502356A1 (enExample)
SG (2) SG186077A1 (enExample)
WO (1) WO2011153514A2 (enExample)
ZA (1) ZA201209381B (enExample)

Families Citing this family (186)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009001636A (es) * 2006-08-16 2009-02-23 Novartis Ag Metodo para elaborar dispersiones solidas de compuestos terapeuticos altamente cristalinos.
CA2663116C (en) 2006-09-22 2014-06-10 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US8809273B2 (en) 2007-03-28 2014-08-19 Pharmacyclics, Inc. Inhibitors of Bruton's tyrosine kinase
PL2176296T3 (pl) 2007-07-16 2012-07-31 Genentech Inc Przeciwciała anty-CD79B i immunokoniugaty i sposoby stosowania
CN101802013B (zh) 2007-07-16 2014-07-02 健泰科生物技术公司 人源化抗cd79b抗体和免疫偶联物及使用方法
CN101965335B (zh) 2008-01-04 2015-01-14 英特利凯恩有限责任公司 某些化学实体、组合物和方法
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
EP2300022A2 (en) 2008-04-25 2011-03-30 Duke University Regulatory b cells and their uses
US20100101977A1 (en) * 2008-06-05 2010-04-29 United Comb & Novelty Corporation Stackable Packaging For Lipped Containers
CA3031835C (en) 2008-06-27 2021-09-07 Celgene Car Llc Heteroaryl compounds and uses thereof
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
CN102159214A (zh) 2008-07-16 2011-08-17 药品循环公司 用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
PE20120602A1 (es) 2009-03-24 2012-05-21 Gilead Calistoga Llc ATROPISOMEROS DE 2-[(6-AMINO-9H-PURIN-9-IL)METIL]-5-METIL-3-o-TOLILQUINAZOLIN-4(3H)-ONA
CN102482277B (zh) 2009-05-05 2017-09-19 达纳-法伯癌症研究所有限公司 表皮生长因子受体抑制剂及治疗障碍的方法
MX342405B (es) 2010-06-03 2016-09-28 Pharmacyclics Inc El uso de inhibidores de la tirosina quinasa de bruton (btk).
US10131875B2 (en) 2010-08-04 2018-11-20 Duke University Regulatory B cells and their uses
CN105566229A (zh) 2010-08-10 2016-05-11 西建阿维拉米斯研究公司 Btk抑制剂的苯磺酸盐及其用途和制备方法
US9238629B2 (en) 2010-11-01 2016-01-19 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
RU2644151C2 (ru) 2010-11-01 2018-02-08 Селджен Авиломикс Рисерч, Инк. Гетероциклические соединения и их применение
WO2012064706A1 (en) 2010-11-10 2012-05-18 Avila Therapeutics, Inc. Mutant-selective egfr inhibitors and uses thereof
US9814740B2 (en) * 2010-12-21 2017-11-14 Duke University Methods and compositions combining immunotherapy with monocyte activation
EP2663309B1 (en) 2011-01-10 2017-03-15 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
MX2013010439A (es) * 2011-03-11 2014-07-09 Gilead Calistoga Llc Tratamientos combinados para neoplasias hematologicas.
CA2833390A1 (en) * 2011-04-28 2012-11-01 Sloan-Kettering Institute For Cancer Research Hsp90 combination therapy
WO2012158795A1 (en) 2011-05-17 2012-11-22 Principia Biopharma Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
AU2012255860C1 (en) 2011-05-17 2015-12-10 Principia Biopharma Inc. Tyrosine kinase inhibitors
EA201490265A1 (ru) 2011-07-13 2014-12-30 Фармасайкликс, Инк. Ингибиторы тирозинкиназы брутона
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
RS58177B1 (sr) 2011-07-19 2019-03-29 Merck Sharp & Dohme 4-imidazopiridazin-1-il-benzamidi i 4-imidazotriazin-1-il-benzamidi kao inhibitori btk
HUE052198T2 (hu) 2011-07-21 2021-04-28 Sumitomo Dainippon Pharma Oncology Inc Heterociklusos protein kináz inhibitorok
KR20230109775A (ko) * 2011-10-19 2023-07-20 파마싸이클릭스 엘엘씨 브루톤 티로신 인산화효소(btk)의 억제제의 용도
US9364476B2 (en) 2011-10-28 2016-06-14 Celgene Avilomics Research, Inc. Methods of treating a Bruton's Tyrosine Kinase disease or disorder
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
CA2854093C (en) 2012-01-19 2016-07-05 Taiho Pharmaceutical Co., Ltd. 3,5-disubstituted alkynylbenzene compound and salt thereof
ES2880109T3 (es) 2012-03-15 2021-11-23 Celgene Car Llc Formas sólidas de un inhibidor de la cinasa del receptor del factor de crecimiento epidérmico
CA2866857C (en) 2012-03-15 2021-03-09 Celgene Avilomics Research, Inc. Salts of an epidermal growth factor receptor kinase inhibitor
HK1206624A1 (en) * 2012-04-11 2016-01-15 Acerta Pharma B.V. Bruton's tyrosine kinase inhibitors for hematopoietic mobilization
TWI662964B (zh) 2012-06-04 2019-06-21 美商製藥有限責任公司 布魯頓氏酪胺酸激酶抑制劑之結晶形式
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
WO2014004707A1 (en) * 2012-06-29 2014-01-03 Principia Biopharma Inc. Formulations comprising ibrutinib
CN104704129A (zh) 2012-07-24 2015-06-10 药品循环公司 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变
US10017739B2 (en) 2012-09-06 2018-07-10 Duke University Methods of expanding and assessing B cells and using expanded B cells to treat disease
SG11201501815UA (en) 2012-09-10 2015-05-28 Principia Biopharma Inc Pyrazolopyrimidine compounds as kinase inhibitors
LT2914296T (lt) 2012-11-01 2018-09-25 Infinity Pharmaceuticals, Inc. Vėžio gydymas, panaudojant p13 kinazės izoformos moduliatorius
BR112015010059A2 (pt) * 2012-11-02 2017-07-11 Pharmacyclics Inc terapia adjuvante com inibidor da quinase da família tec
CN104854107A (zh) 2012-11-15 2015-08-19 药品循环公司 作为激酶抑制剂的吡咯并嘧啶化合物
TW201427668A (zh) * 2012-11-20 2014-07-16 Celgene Avilomics Res Inc 治療和布魯頓（ｂｒｕｔｏｎ’ｓ）酪胺酸激酶相關之疾病或失調的方法
EP2922827A4 (en) * 2012-11-20 2016-06-08 Celgene Avilomics Res Inc METHOD FOR THE TREATMENT OF A DISEASE OR DISEASE RELATED TO BRUTON TYROSINE KINASE
TW201427666A (zh) * 2012-11-20 2014-07-16 Celgene Avilomics Res Inc 治療和布魯頓（ｂｒｕｔｏｎ’ｓ）酪胺酸激酶相關之疾病或失調的方法
CN103848810A (zh) 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
WO2014096367A1 (en) * 2012-12-21 2014-06-26 Servicio Andaluz De Salud Expression of beta2-microglobulin as a prognostic marker for tumour immune escape and resistance to cancer immunotherapy and a diagnostic biomarker for patient selection for specific gene therapy
EP2935226A4 (en) 2012-12-21 2016-11-02 Celgene Avilomics Res Inc HETEROARYL COMPOUNDS AND USES THEREOF
WO2014113932A1 (en) * 2013-01-23 2014-07-31 Merck Sharp & Dohme Corp. Btk inhibitors
US9481682B2 (en) 2013-01-23 2016-11-01 Merck Sharp & Dohme Corp. Substituted benzamides and substituted pyridinecarboxamides as Btk inhibitors
US9145387B2 (en) 2013-02-08 2015-09-29 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
CN105073115A (zh) * 2013-03-14 2015-11-18 药品循环有限责任公司 布鲁顿氏酪氨酸激酶抑制剂和cyp3a4抑制剂的组合
TR201911151T4 (tr) 2013-03-14 2019-08-21 Tolero Pharmaceuticals Inc Jak2 ve alk2 inhibitörleri ve bunların kullanım yöntemleri.
CN105492011A (zh) 2013-04-08 2016-04-13 丹尼斯·M·布朗 不理想给药化学化合物的治疗增效
HK1215374A1 (zh) * 2013-04-08 2016-08-26 Pharmacyclics Llc 依鲁替尼联合疗法
US8957080B2 (en) 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
SG11201506764WA (en) 2013-04-25 2015-09-29 Beigene Ltd Fused heterocyclic compounds as protein kinase inhibitors
GB201309085D0 (en) 2013-05-20 2013-07-03 Redx Pharma Ltd Compounds
SG11201509842SA (en) * 2013-05-30 2015-12-30 Infinity Pharmaceuticals Inc Treatment of cancers using pi3 kinase isoform modulators
EP3023101B1 (en) 2013-07-18 2020-08-19 Taiho Pharmaceutical Co., Ltd. Therapeutic agent for fgfr inhibitor-resistant cancer
KR101974254B1 (ko) * 2013-07-18 2019-04-30 다이호야쿠힌고교 가부시키가이샤 Fgfr 저해제의 간헐 투여용 항종양제
TWI649081B (zh) 2013-08-02 2019-02-01 製藥公司 治療固態腫瘤之方法
EP3033079B1 (en) 2013-08-12 2018-10-31 Pharmacyclics LLC Methods for the treatment of her2 amplified cancer
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
EP3044234B9 (en) 2013-09-13 2020-08-26 BeiGene Switzerland GmbH Anti-pd1 antibodies and their use as therapeutics and diagnostics
CA2925124A1 (en) 2013-09-30 2015-04-02 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
WO2015054197A1 (en) * 2013-10-10 2015-04-16 Acetylon Pharmaceuticals, Inc. Hdac inhibitors, alone or in combination with btk inhibitors, for treating non-hodgkin's lymphoma
US9795604B2 (en) 2013-10-25 2017-10-24 Pharmacyclics Llc Methods of treating and preventing graft versus host disease
CA2929826C (en) * 2013-11-06 2022-08-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for selecting and treating lymphoma types
PH12020552048A1 (en) * 2013-12-02 2022-05-11 Pharmacyclics Llc Methods of treating and preventing alloantibody driven chronic graft versus host disease
EP3076974A1 (en) * 2013-12-05 2016-10-12 Acerta Pharma B.V. Therapeutic combination of a pi3k inhibitor and a btk inhibitor
WO2015095102A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Btk inhibitors
US9637486B2 (en) 2013-12-20 2017-05-02 Merck Sharp & Dohme Corp. Btk inhibitors
US9415049B2 (en) * 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
WO2015110923A2 (en) * 2014-01-21 2015-07-30 Acerta Pharma B.V. Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor
US10272083B2 (en) 2014-01-21 2019-04-30 Acerta Pharma B.V. Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
US10441654B2 (en) 2014-01-24 2019-10-15 Children's Hospital Of Eastern Ontario Research Institute Inc. SMC combination therapy for the treatment of cancer
KR20160117614A (ko) 2014-02-21 2016-10-10 프린시피아 바이오파마, 인코퍼레이티드 Btk 억제제의 염 및 고체 형태
JP2017509336A (ja) 2014-03-20 2017-04-06 ファーマサイクリックス エルエルシー ホスホリパーゼｃガンマ２及び耐性に関連した変異
US9937171B2 (en) 2014-04-11 2018-04-10 Acerta Pharma B.V. Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinase
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
GB201410430D0 (en) 2014-06-11 2014-07-23 Redx Pharma Ltd Compounds
WO2015193740A2 (en) 2014-06-17 2015-12-23 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor and/or a jak-2 inhibitor
TWI726608B (zh) 2014-07-03 2021-05-01 英屬開曼群島商百濟神州有限公司 抗pd-l1抗體及其作為治療及診斷之用途
WO2016019233A1 (en) 2014-08-01 2016-02-04 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
JP2017523188A (ja) * 2014-08-01 2017-08-17 ファーマサイクリックス エルエルシー Ｂｔｋ阻害剤を伴う治療に対するｄｌｂｃｌの応答を予測するためのバイオマーカー
SG11201700849XA (en) 2014-08-07 2017-03-30 Pharmacyclics Llc Novel formulations of a bruton's tyrosine kinase inhibitor
AU2015300966A1 (en) 2014-08-08 2017-02-16 Janssen Pharmaceutica Nv Bruton's tyrosine kinase inhibitor combinations and uses thereof
SMT202100674T1 (it) 2014-08-11 2022-01-10 Acerta Pharma Bv Combinazioni terapeutiche di un inibitore di btk e un inibitore di bcl-2
TW201609099A (zh) * 2014-08-11 2016-03-16 艾森塔製藥公司 使用布魯頓（Ｂｒｕｔｏｎ）氏酪胺酸激酶（ＢＴＫ）抑制劑以治療慢性淋巴球性白血病和小淋巴球性白血病之方法
ES2741785T3 (es) 2014-08-13 2020-02-12 Celgene Car Llc Formas y composiciones de un inhibidor de ERK
CA2979671C (en) 2014-09-23 2020-03-10 Genentech, Inc. Methods of using anti-cd79b immunoconjugates
WO2016054627A1 (en) * 2014-10-03 2016-04-07 Ohio State Innovation Foundation Biomarkers of bruton tyrosine kinase inhibitor resistance
TW201628622A (zh) * 2014-11-17 2016-08-16 製藥公司 Tlr抑制劑與布魯頓氏(bruton's)酪胺酸激酶抑制劑之組合
AU2015364335B2 (en) 2014-12-18 2020-11-26 Principia Biopharma Inc. Treatment of pemphigus
EP3236968A4 (en) * 2014-12-23 2018-08-01 Pharmacyclics LLC Btk inhibitor combinations and dosing regimen
WO2016106652A1 (en) * 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Biarylether imidazopyrazine btk inhibitors
WO2016123504A1 (en) * 2015-01-30 2016-08-04 Pharmacyclics Llc Btk inhibitor combinations and multidrug-resistance
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
MX373612B (es) 2015-03-31 2020-05-07 Taiho Pharmaceutical Co Ltd Cristal del compuesto alquinil benceno 3,5-disustituido.
EA033992B1 (ru) 2015-04-06 2019-12-17 Янссен Фармацевтика Нв Композиции, содержащие ибрутиниб
EP3284466A4 (en) 2015-04-13 2018-12-05 Daiichi Sankyo Company, Limited Treatment method combining mdm2 inhibitor and btk inhibitor
WO2016189014A1 (en) 2015-05-26 2016-12-01 Morphosys Ag Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof
EP3313839A1 (en) * 2015-06-24 2018-05-02 Principia Biopharma Inc. Tyrosine kinase inhibitors
IL293821A (en) 2015-07-02 2022-08-01 Acerta Pharma Bv Solid forms and formulations of (S)-4-(8-amino-3-(1-(but-2-aminoyl)pyrrolidine-2-yl)imidazo[5,1-yl]pyrazin-1-yl)-en- (pyridine-2-yl)benzamide
US20170027941A1 (en) * 2015-07-31 2017-02-02 Pharmacyclics Llc Bruton's Tyrosine Kinase Inhibitor Combinations and Uses Thereof
MX2018002554A (es) * 2015-08-31 2018-08-14 Pharmacyclics Llc Combinaciones de inhibidores de btk para tratar mieloma multiple.
MA44909A (fr) * 2015-09-15 2018-07-25 Acerta Pharma Bv Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
CN114685516A (zh) 2015-09-16 2022-07-01 洛克索肿瘤学股份有限公司 用于治疗癌症的作为btk抑制剂的吡唑并嘧啶衍生物
MA43377A (fr) 2015-12-04 2021-05-19 Hutchinson Fred Cancer Res Méthodes et compositions liées à la toxicité associée à la thérapie cellulaire
EP3390395B1 (en) 2015-12-16 2020-09-09 Loxo Oncology, Inc. Compounds useful as kinase inhibitors
CA3236518A1 (en) 2016-02-29 2017-09-08 F. Hoffmann-La Roche Ag Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase
KR102793563B1 (ko) 2016-03-04 2025-04-11 다이호야쿠힌고교 가부시키가이샤 악성 종양 치료용 제제 및 조성물
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
JP2019515909A (ja) 2016-04-19 2019-06-13 アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 慢性リンパ性白血病の治療を目的とするｈｄａｃ阻害剤単独またはｂｔｋ阻害剤との配合物
BR112018077021A2 (pt) 2016-06-24 2019-04-02 Infinity Pharmaceuticals, Inc. terapias de combinação
IL293621B2 (en) 2016-06-29 2023-09-01 Principia Biopharma Inc Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[4,3-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4 -Methyl-4-[4-(oxane-3-yl)piperazine-1-yl)penta-2-ananitrile
JP6993056B2 (ja) 2016-07-05 2022-02-15 ベイジーン リミテッド 癌治療のためのｐｄ－１アンタゴニスト及びｒａｆ阻害剤の組合せ
MX384627B (es) 2016-08-16 2025-03-14 Beigene Ltd Forma cristalina de (s)-7-(1-acriloilpiperidin-4-il)-2-(4-fenoxifenil)-4,5,6,7-tetra-hidropirazolo[1,5-a]pirimidin-3-carboxamida, preparacion y usos de la misma
HUE065528T2 (hu) 2016-08-19 2024-06-28 Beigene Switzerland Gmbh Zanubrutinib kombinációja anti-CD20 vagy anti-PD-1 antitesttel rák kezelésében történõ alkalmazásra
MA46285A (fr) 2016-09-19 2019-07-31 Mei Pharma Inc Polythérapie
JP7590810B2 (ja) 2016-10-06 2024-11-27 ヤンセン ファーマシューティカ エヌ．ベー． Ｂｔｋ阻害剤を調製するための方法および中間体
DK3532098T3 (da) 2016-10-28 2021-05-25 Morphosys Ag Kombination af anti-cd19-antistof med en bcl-2-inhibitor og anvendelser deraf
CN110139669A (zh) 2016-11-03 2019-08-16 朱诺治疗学股份有限公司 T细胞疗法和btk抑制剂的组合疗法
CN110545826A (zh) 2016-12-03 2019-12-06 朱诺治疗学股份有限公司 用于与激酶抑制剂组合使用治疗性t细胞的方法和组合物
US10174018B2 (en) 2016-12-13 2019-01-08 Princeton Drug Discovery Inc Protein kinase inhibitors
CN110248668B (zh) 2016-12-15 2023-05-30 杜克大学 用于消耗调节性b10细胞的抗体和方法以及与免疫检查点抑制剂的联用
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
CN110461847B (zh) 2017-01-25 2022-06-07 百济神州有限公司 (S)-7-(1-(丁-2-炔酰基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氢吡唑并[1,5-a]嘧啶-3-甲酰胺的结晶形式、其制备及用途
GB201703876D0 (en) 2017-03-10 2017-04-26 Berlin-Chemie Ag Pharmaceutical combinations
AU2018275891B2 (en) 2017-06-02 2025-02-27 Juno Therapeutics, Inc. Articles of manufacture and methods related to toxicity associated with cell therapy
AU2018275894B2 (en) 2017-06-02 2025-04-24 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
KR102757960B1 (ko) 2017-06-26 2025-01-22 베이진 엘티디 간세포암(hepatocellular carcinoma: HCC)에 대한 면역 치료
AU2018291032A1 (en) 2017-06-29 2020-01-16 Juno Therapeutics, Inc. Mouse model for assessing toxicities associated with immunotherapies
CN110997677A (zh) 2017-08-12 2020-04-10 百济神州有限公司 具有改进的双重选择性的Btk抑制剂
WO2019046832A1 (en) 2017-09-01 2019-03-07 Juno Therapeutics, Inc. GENE EXPRESSION AND EVALUATION OF RISK OF DEVELOPMENT OF TOXICITY FOLLOWING CELL THERAPY
TW201922256A (zh) 2017-10-27 2019-06-16 中國大陸商浙江導明醫藥科技有限公司 治療淋巴樣惡性疾病之方法
US11564946B2 (en) 2017-11-01 2023-01-31 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
CN111801334B (zh) 2017-11-29 2023-06-09 百济神州瑞士有限责任公司 使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤
CZ2017787A3 (cs) 2017-12-08 2019-06-19 Zentiva, K.S. Farmaceutické kompozice obsahující ibrutinib
JP6918204B2 (ja) 2018-03-19 2021-08-11 大鵬薬品工業株式会社 アルキル硫酸ナトリウムを含む医薬組成物
WO2019195753A1 (en) 2018-04-05 2019-10-10 Tolero Pharmaceuticals, Inc. Axl kinase inhibitors and use of the same
CN117959303A (zh) 2018-04-13 2024-05-03 住友制药肿瘤公司 用于治疗骨髓增殖性肿瘤和与癌症相关的纤维化的pim激酶抑制剂
WO2019213184A1 (en) 2018-05-03 2019-11-07 Juno Therapeutics, Inc. Combination therapy of a chimeric antigen receptor (car) t cell therapy and a kinase inhibitor
JP7695078B2 (ja) 2018-06-15 2025-06-18 ヤンセン ファーマシューティカ エヌ．ベー． イブルチニブを含む配合物／組成物
JP2021530554A (ja) 2018-07-26 2021-11-11 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド 異常なａｃｖｒ１発現を伴う疾患を処置するための方法およびそこで使用するためのａｃｖｒ１阻害剤
CN109481441A (zh) * 2018-10-31 2019-03-19 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和新型甲氧基酞嗪酮类btk抑制剂联合用药物组合物及其应用
CN109394765A (zh) * 2018-10-31 2019-03-01 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和对苯基酞嗪酮类btk抑制剂联合用药物组合物及其应用
CN109331005A (zh) * 2018-10-31 2019-02-15 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和氟酞嗪类btk抑制剂联合用药物组合物及其应用
CN109331018A (zh) * 2018-10-31 2019-02-15 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和硝基酞嗪酮btk抑制剂联合用药物组合物及其应用
CN109394766A (zh) * 2018-10-31 2019-03-01 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和对苯硝基酞嗪酮类btk抑制剂联合用药物组合物及其应用
CN109172562A (zh) * 2018-10-31 2019-01-11 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和甲氧基酞嗪酮类btk抑制剂联合用药物组合物及其应用
CN109223759A (zh) * 2018-10-31 2019-01-18 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和新型酞嗪酮类btk抑制剂联合用药物组合物及其应用
CN109481442A (zh) * 2018-10-31 2019-03-19 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和邻苯基酞嗪酮类btk抑制剂联合用药物组合物及其应用
CN109276571A (zh) * 2018-10-31 2019-01-29 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和新型硝基酞嗪酮btk抑制剂联合用药物组合物及其应用
CN109288841A (zh) * 2018-10-31 2019-02-01 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和对苯氟酞嗪酮类btk抑制剂联合用药物组合物及其应用
CN109481443A (zh) * 2018-10-31 2019-03-19 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和邻苯氟酞嗪酮类btk抑制剂联合用药物组合物及其应用
CN109481444A (zh) * 2018-10-31 2019-03-19 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和酞嗪类btk抑制剂联合用药物组合物及其应用
DK3886894T3 (da) 2018-11-30 2024-06-03 Juno Therapeutics Inc Fremgangsmåder til dosering og behandling af b-cellemaligniteter i adoptiv celleterapi
ES2981569T3 (es) 2018-11-30 2024-10-09 Juno Therapeutics Inc Métodos de tratamiento usando terapia celular adoptiva
US11471456B2 (en) 2019-02-12 2022-10-18 Sumitomo Pharma Oncology, Inc. Formulations comprising heterocyclic protein kinase inhibitors
CA3129623A1 (en) 2019-02-22 2020-08-27 Janssen Pharmaceutica Nv Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifluoromethyl)pyridin-4-yl)-1h-pyrazole-4-carboxamide monohydrate
MX2021009863A (es) 2019-03-21 2021-11-12 Onxeo Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer.
EP3953345B1 (en) 2019-04-11 2023-04-05 Janssen Pharmaceutica NV Pyridine rings containing derivatives as malt1 inhibitors
TW202446397A (zh) 2019-06-10 2024-12-01 瑞士商百濟神州瑞士有限責任公司 一種含有布魯頓氏酪胺酸激酶抑制劑的口服固體錠劑及其製備方法
WO2020260453A1 (en) * 2019-06-25 2020-12-30 Université de Paris Detection of relb activation for predicting a prognostic in b-cell lymphoma
CN110724143B (zh) * 2019-10-09 2021-03-23 清华大学 一种靶向btk蛋白降解化合物的制备及其在治疗自身免疫系统疾病与肿瘤中的应用
CN115209899A (zh) 2019-10-14 2022-10-18 普林斯匹亚生物制药公司 通过施用(R)-2-[3-[4-氨基-3-(2-氟-4-苯氧基-苯基)吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(氧杂环丁-3-基)哌嗪-1-基]戊-2-烯腈治疗免疫性血小板减少症的方法
EP4048279A1 (en) * 2019-10-21 2022-08-31 Celgene Corporation Methods of treating chronic lymphocytic leukemia using 2-(2,6-dioxopiperidin-3yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1. 3-dione
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
IL293393A (en) 2019-12-06 2022-07-01 Juno Therapeutics Inc Methods related to toxicity and response associated with cell therapy for treating b cell malignancies
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
EP4093741A1 (en) 2020-01-22 2022-11-30 Principia Biopharma Inc. Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
US11433072B1 (en) 2021-06-10 2022-09-06 Hikma Pharmaceuticals USA, Inc. Oral dosage forms of ibrutinib
WO2023014817A1 (en) 2021-08-03 2023-02-09 Syros Pharmaceuticals, Inc. Compositions and methods for treating lymphomas with a cdk7 inhibitor in combination with a btk inhibitor
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
US11786531B1 (en) 2022-06-08 2023-10-17 Beigene Switzerland Gmbh Methods of treating B-cell proliferative disorder
EP4611753A1 (en) 2022-10-31 2025-09-10 Sumitomo Pharma America, Inc. Pim1 inhibitor for treating myeloproliferative neoplasms
DE202023107671U1 (de) 2023-12-27 2024-01-31 Aglave Hanmant Raghunath Umweltfreundliches System zur Vorbeugung und Bekämpfung von bodenbürtigen Krankheiten bei Sojabohnen durch Präzisionslandwirtschaft
CN119040247B (zh) * 2024-10-30 2025-02-18 北京三元食品股份有限公司 乳酸多韦替尼在上调细胞中乳铁蛋白表达中的应用

Family Cites Families (351)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3547119A (en) 1967-12-08 1970-12-15 Baxter Laboratories Inc Catheter assembly
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3598122A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3993073A (en) 1969-04-01 1976-11-23 Alza Corporation Novel drug delivery device
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4069307A (en) 1970-10-01 1978-01-17 Alza Corporation Drug-delivery device comprising certain polymeric materials for controlled release of drug
US3731683A (en) 1971-06-04 1973-05-08 Alza Corp Bandage for the controlled metering of topical drugs to the skin
US3996934A (en) 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US3742951A (en) 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
BE795384A (fr) 1972-02-14 1973-08-13 Ici Ltd Pansements
US3921636A (en) 1973-01-15 1975-11-25 Alza Corp Novel drug delivery device
US3993072A (en) 1974-08-28 1976-11-23 Alza Corporation Microporous drug delivery device
US3972995A (en) 1975-04-14 1976-08-03 American Home Products Corporation Dosage form
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4031894A (en) 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
US4060084A (en) 1976-09-07 1977-11-29 Alza Corporation Method and therapeutic system for providing chemotherapy transdermally
US4201211A (en) 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
JPS5562012A (en) 1978-11-06 1980-05-10 Teijin Ltd Slow-releasing preparation
US4230105A (en) 1978-11-13 1980-10-28 Merck & Co., Inc. Transdermal delivery of drugs
US4360019A (en) 1979-02-28 1982-11-23 Andros Incorporated Implantable infusion device
US4229447A (en) 1979-06-04 1980-10-21 American Home Products Corporation Intraoral methods of using benzodiazepines
US4291015A (en) 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator
US4692147A (en) 1980-04-02 1987-09-08 Medtronic, Inc. Drug administration device
US4311137A (en) 1980-04-30 1982-01-19 Sherwood Medical Industries Inc. Infusion device
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4476116A (en) 1982-12-10 1984-10-09 Syntex (U.S.A.) Inc. Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
US5116817A (en) 1982-12-10 1992-05-26 Syntex (U.S.A.) Inc. LHRH preparations for intranasal administration
US4531937A (en) 1983-01-24 1985-07-30 Pacesetter Systems, Inc. Introducer catheter apparatus and method of use
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4725852A (en) 1985-05-09 1988-02-16 Burlington Industries, Inc. Random artificially perturbed liquid apparatus and method
US4755386A (en) 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
US4755173A (en) 1986-02-25 1988-07-05 Pacesetter Infusion, Ltd. Soft cannula subcutaneous injection set
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
JPH01167840A (ja) 1987-12-24 1989-07-03 Konica Corp 新規な写真用シアンカプラー
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5739136A (en) 1989-10-17 1998-04-14 Ellinwood, Jr.; Everett H. Intraoral dosing method of administering medicaments
US5633009A (en) 1990-11-28 1997-05-27 Sano Corporation Transdermal administration of azapirones
DE69222847T3 (de) 1991-04-16 2005-09-15 Nippon Shinyaku Co., Ltd. Verfahren zur herstellung einer festen dispersion
EP0773227A1 (en) 1991-09-18 1997-05-14 Affymax Technologies N.V. Diverse collections of oligomers in use to prepare drugs, diagnostic reagents, pesticides or herbicides
DE69233087T2 (de) 1991-11-22 2003-12-24 Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) Verfahren zur Herstellung von Polymerarrays
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
HU227530B1 (en) 1991-11-22 2011-07-28 Warner Chilcott Company Delayed-release compositions containing risedronate and process for their production
AU3482493A (en) 1992-01-22 1993-09-01 New England Deaconess Hospital Novel protein tyrosine kinases
US5461140A (en) 1992-04-30 1995-10-24 Pharmaceutical Delivery Systems Bioerodible polymers for solid controlled release pharmaceutical compositions
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
WO1994008568A1 (fr) 1992-10-16 1994-04-28 Nippon Shinyaku Co., Ltd. Procede pour fabriquer des matrices de cire
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
ES2174992T3 (es) 1992-12-29 2002-11-16 Abbott Lab Productos intermediarios para la obtencion de compuestos inhibidores de proteasas retrovirales.
US5545143A (en) 1993-01-21 1996-08-13 T. S. I. Medical Device for subcutaneous medication delivery
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US6326469B1 (en) 1994-04-22 2001-12-04 Sugen, Inc. Megakaryocytic protein tyrosine kinases
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5665378A (en) 1994-09-30 1997-09-09 Davis; Roosevelt Transdermal therapeutic formulation
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US5530012A (en) 1994-12-22 1996-06-25 Bristol-Myers Squibb Co. 3-alkoxybenzylpiperidine derivatives as melatonergic agents
US5643207A (en) 1995-04-28 1997-07-01 Medtronic, Inc. Implantable techniques for infusing a therapeutic agent with endogenous bodily fluid
JPH11505258A (ja) 1995-05-17 1999-05-18 セダーシナイ メディカル センター 小腸における消化および吸収を改善させる脂肪酸を含む組成物
US5593997A (en) 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
US5994348A (en) 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US5545531A (en) 1995-06-07 1996-08-13 Affymax Technologies N.V. Methods for making a device for concurrently processing multiple biological chip assays
US5856174A (en) 1995-06-29 1999-01-05 Affymetrix, Inc. Integrated nucleic acid diagnostic device
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
EP1240899A3 (en) 1996-01-23 2004-05-19 Ribapharm, Inc. Modulation of Th1/Th2 Cytokine expression by Ribavirin and Ribavirin analogs in actived T-Lymphocytes for treating HCV infections
EP0880598A4 (en) 1996-01-23 2005-02-23 Affymetrix Inc RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM
CH690773A5 (de) 1996-02-01 2001-01-15 Novartis Ag Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
US6923983B2 (en) 1996-02-19 2005-08-02 Acrux Dds Pty Ltd Transdermal delivery of hormones
US6929801B2 (en) 1996-02-19 2005-08-16 Acrux Dds Pty Ltd Transdermal delivery of antiparkinson agents
HUP0004421A3 (en) 1996-04-23 2002-10-28 Vertex Pharmaceuticals Inc Cam Urea derivatives and pharmaceutical compositions containing them, use thereof for the treatment of deseases mediated by impdh enzyme
US5820589A (en) 1996-04-30 1998-10-13 Medtronic, Inc. Implantable non-invasive rate-adjustable pump
AU3176297A (en) 1996-06-25 1998-01-14 Novartis Ag Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof
EP1254911A1 (en) 1996-10-16 2002-11-06 ICN Pharmaceuticals, Inc. Monocyclic L-nucleosides, analogs and uses thereof
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6893636B2 (en) 1997-02-20 2005-05-17 Biogen Idec Ma Inc. Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
AU6701598A (en) 1997-03-14 1998-09-29 Vertex Pharmaceuticals Incorporated Inhibitors of impdh enzyme
HUP0001507A3 (en) 1997-03-19 2002-01-28 Abbott Gmbh & Co Kg Pyrrolo [2,3-d] pyrimidine derivatives, process for their preparation, their use and pharmaceutical compositions containing them
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
WO1999023254A1 (en) 1997-10-31 1999-05-14 Affymetrix, Inc. Expression profiles in adult and fetal organs
GB2332325A (en) 1997-12-10 1999-06-16 Snell & Wilcox Ltd Video signal spatial interpolation for de-interlacing processing
US5869090A (en) 1998-01-20 1999-02-09 Rosenbaum; Jerry Transdermal delivery of dehydroepiandrosterone
US7390619B1 (en) 1998-02-11 2008-06-24 Maxygen, Inc. Optimization of immunomodulatory properties of genetic vaccines
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
HUP0102661A2 (hu) 1998-04-17 2001-11-28 Parker Hughes Institute BTK-inhibitorok és a BTK-inhibitorok azonosítására szolgáló eljárások, valamint alkalmazásuk
US6303652B1 (en) 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
US6998233B2 (en) 1998-06-26 2006-02-14 Sunesis Pharmaceuticals, Inc. Methods for ligand discovery
US6335155B1 (en) 1998-06-26 2002-01-01 Sunesis Pharmaceuticals, Inc. Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
US20050287596A9 (en) 1998-06-26 2005-12-29 Braisted Andrew C Novel ligands and libraries of ligands
US6946144B1 (en) 1998-07-08 2005-09-20 Oryxe Transdermal delivery system
US7087236B1 (en) 1998-09-01 2006-08-08 Merrion Research I Limited Method for inducing a cell-mediated immune response and improved parenteral vaccine formulations thereof
CA2345722A1 (en) 1998-09-28 2000-04-06 Albert Edge Determining resistance to treatment for hepatitis c virus
AT411956B (de) 1998-10-01 2004-08-26 Masterfoods Austria Ohg Verfahren zur herstellung eines waffelproduktes, anlage zur durchführung dieses verfahrens und nach diesem verfahren hergestelltes waffelprodukt
US6824768B2 (en) 1998-12-18 2004-11-30 Schering Corporation Ribavirin-pegylated interferon alfa induction HCV combination therapy
US6198966B1 (en) 1999-02-26 2001-03-06 Medtronic, Inc. Recirculating implantable drug delivery system
EP1964561A1 (en) 1999-03-19 2008-09-03 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US6306897B1 (en) 1999-03-19 2001-10-23 Parker Hughes Institute Calanolides for inhibiting BTK
AU4463300A (en) 1999-04-19 2000-11-02 Schering Corporation Hcv combination therapy, containing ribavirin in association with antioxidants
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
DK1212327T3 (da) 1999-09-17 2003-12-15 Abbott Gmbh & Co Kg Pyrazolopyrimidiner som terapeutiske midler
US6506769B2 (en) 1999-10-06 2003-01-14 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
DE60014130T2 (de) 1999-10-06 2006-03-09 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Heterocyclische verbindungen verwendbar als tyrosinkinase inhibitoren
AU1086501A (en) 1999-10-15 2001-04-30 Carnegie Institution Of Washington Rna interference pathway genes as tools for targeted genetic interference
EP1227844A2 (en) 1999-10-29 2002-08-07 Pharmacyclics, Inc. Compositions for treating atheroma and neoplastic tissue
CA2390857A1 (en) 1999-11-30 2001-06-14 Fatih M. Uckun Inhibitors of collagen-induced platelet aggregation
CA2394650A1 (en) 1999-12-17 2001-06-21 Chi B. Vu Novel heterocycles
US7835970B1 (en) 2000-02-02 2010-11-16 Cmvt, Llc Method and system for automated auction and tender of complex multi-variable commodities
GB0005345D0 (en) 2000-03-06 2000-04-26 Mathilda & Terence Kennedy Ins Methods of treating sepsis septic shock and inflammation
JP2003525907A (ja) 2000-03-09 2003-09-02 シェーリング コーポレイション Ｈｉｖ免疫アジュバント治療
WO2001077384A2 (de) 2000-04-07 2001-10-18 Epigenomics Ag DETEKTION VON SNPs UND CYTOSIN-METHYLIERUNGEN
US6673333B1 (en) 2000-05-04 2004-01-06 Research Corporation Technologies, Inc. Functional MRI agents for cancer imaging
AU8322401A (en) 2000-08-09 2002-02-18 Univ California Indole compounds useful for the treatment of cancer
JP2004511513A (ja) 2000-10-18 2004-04-15 シェリング・コーポレーション リバビリン−ＰＥＧ化インターフェロンαＨＣＶ併用治療
JP2004533209A (ja) 2000-10-23 2004-11-04 ブリストル−マイヤーズ　スクイブ　カンパニー ブルトンチロシンキナーゼおよびブルトンチロシンキナーゼ媒体のモデュレーターおよびその同定方法および骨粗鬆症および関連疾患状態の治療および予防におけるその使用
CN100391967C (zh) 2000-11-20 2008-06-04 布里斯托尔-迈尔斯斯奎布公司 丙型肝炎三肽抑制剂
US20020094545A1 (en) 2000-11-30 2002-07-18 Harris Paul E. Growth of human dendritic cells for cancer immunotherapy in closed system using microcarrier beads
AU2002232492A1 (en) 2000-12-06 2002-06-18 Pharmacia Corporation Rapidly dispersing pharmaceutical composition comprising effervescent agents
EP2357187A1 (en) 2000-12-12 2011-08-17 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US6465014B1 (en) 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
MXPA03008560A (es) 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
AR036993A1 (es) 2001-04-02 2004-10-20 Wyeth Corp Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
US8306897B2 (en) 2001-05-04 2012-11-06 Stockshield, Inc. Method and system for insuring against investment loss
US20030103938A1 (en) 2001-05-09 2003-06-05 Alk-Abello A/S Pharmaceutical compositions for preventing or treating Th1 and Th2 cell related diseases by modulating the Th1/Th2 ratio
EP1463742A4 (en) 2001-06-21 2006-05-10 Ariad Pharma Inc NEW PYRAZOLO AND PYRROLO PYRIMIDINES AND THEIR USES
GB0116249D0 (en) 2001-07-05 2001-08-29 Imp College Innovations Ltd Methods
CA2450777C (en) 2001-08-10 2013-04-09 Novartis Ag Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia
US20030119060A1 (en) 2001-08-10 2003-06-26 Desrosiers Peter J. Apparatuses and methods for creating and testing pre-formulations and systems for same
WO2003016338A1 (en) 2001-08-15 2003-02-27 Parker Hughes Institute Crystal structure of the btk kinase domain
US6960563B2 (en) 2001-08-31 2005-11-01 Morton Grove Pharmaceuticals, Inc. Spontaneous emulsions containing cyclosporine
US7622260B2 (en) 2001-09-05 2009-11-24 The Brigham And Women's Hospital, Inc. Diagnostic and prognostic tests
JP4391237B2 (ja) 2001-11-21 2009-12-24 サネシス ファーマシューティカルズ， インコーポレイテッド リガンド発見のための方法
US20030175761A1 (en) 2001-12-07 2003-09-18 Sabath Daniel E. Identification of genes whose expression patterns distinguish benign lymphoid tissue and mantle cell, follicular, and small lymphocytic lymphoma
US20050084905A1 (en) 2002-03-21 2005-04-21 Prescott John C. Identification of kinase inhibitors
US7329502B2 (en) 2002-04-25 2008-02-12 The United States Of America As Represented By The Department Of Health And Human Services ZAP-70 expression as a marker for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
GB2388594A (en) 2002-05-16 2003-11-19 Bayer Ag Imidazo-triazine PDE 4 inhibitors
AU2003251900B2 (en) 2002-07-15 2008-12-18 President And Fellows Of Harvard College Methods and compositions for modulating T helper (Th) cell development and function
CN103169708B (zh) 2002-07-29 2018-02-02 里格尔药品股份有限公司 用2,4‑嘧啶二胺化合物治疗或者预防自体免疫性疾病的方法
AU2003257094A1 (en) 2002-08-08 2004-02-25 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted benzimidazole compounds
AU2003300184B8 (en) 2002-12-30 2009-12-03 3M Innovative Properties Company Immunostimulatory combinations
GB0303910D0 (en) 2003-02-20 2003-03-26 Merck Sharp & Dohme Therapeutic agents
US7687506B2 (en) 2003-04-11 2010-03-30 The Regents Of The University Of California Selective serine/threonine kinase inhibitors
US20050008640A1 (en) 2003-04-23 2005-01-13 Wendy Waegell Method of treating transplant rejection
EP1473039A1 (en) 2003-05-02 2004-11-03 Centre National De La Recherche Scientifique (Cnrs) Use of inhibitors and antisense oligonucleotides of BTK for the treatment of proliferative mastocytosis
US20070032457A1 (en) 2003-05-16 2007-02-08 Blatt Lawrence M Combination therapy for cancer treatment
WO2005014599A1 (en) 2003-06-04 2005-02-17 Cellular Genomics, Inc. Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds
US6950493B2 (en) 2003-06-25 2005-09-27 Besson Guy M Dynamic multi-spectral CT imaging
US7393848B2 (en) 2003-06-30 2008-07-01 Cgi Pharmaceuticals, Inc. Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds
US8131475B2 (en) 2003-09-03 2012-03-06 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods for identifying, diagnosing, and predicting survival of lymphomas
CA2537254A1 (en) 2003-09-03 2005-03-17 Government Of The United States Of America, As Represented By Secretary, Department Of Health And Human Services Methods for identifying, diagnosing, and predicting survival of lymphomas
JP2005089352A (ja) 2003-09-16 2005-04-07 Kissei Pharmaceut Co Ltd 新規なイミダゾ［１，５−ａ］ピラジン誘導体、それを含有する医薬組成物およびそれらの用途
CN1886156A (zh) 2003-09-30 2006-12-27 特莱索恩儿童健康研究院 免疫治疗方法
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
ES2372694T3 (es) 2003-10-15 2012-01-25 OSI Pharmaceuticals, LLC Inhibidores de tirosina cinasa de imidazo[1,5-a]pirazina.
US20070196395A1 (en) 2003-12-12 2007-08-23 Mackerell Alexander Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain
US20050153990A1 (en) 2003-12-22 2005-07-14 Watkins William J. Phosphonate substituted kinase inhibitors
US20070281907A1 (en) 2003-12-22 2007-12-06 Watkins William J Kinase Inhibitor Phosphonate Conjugates
PL1701698T3 (pl) 2004-01-08 2008-03-31 Wyeth Corp Prasowana bezpośrednio kompozycja farmaceutyczna do podawania doustnego CCI-779
AU2005228845A1 (en) 2004-01-26 2005-10-13 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
JP2007520559A (ja) 2004-02-03 2007-07-26 アボット・ラボラトリーズ 治療薬としてのアミノベンゾオキサゾール類
WO2006002119A2 (en) 2004-06-18 2006-01-05 Gpc Biotech, Inc. Kinase inhibitors for treating cancers
ITMI20041314A1 (it) 2004-06-30 2004-09-30 Nuvera Fuel Cells Europ Srl Dispositivo di raffreddamento per celle a combustibili a membrana
BRPI0511445A (pt) 2004-07-08 2007-12-26 Cellectar Llc métodos para distinguir uma estrutura benigna de tecido maligno, para monitorar eficiência do tratamento de cáncer, e para distinguir sub-regiões morfológicas e funcionais de região de tecido selecionado, composição e uso de análogo de éter fosfolipìdico
TW200613306A (en) 2004-07-20 2006-05-01 Osi Pharm Inc Imidazotriazines as protein kinase inhibitors
US20060063190A1 (en) 2004-09-22 2006-03-23 Tripath Imaging, Inc Methods and compositions for evaluating breast cancer prognosis
WO2006036941A2 (en) 2004-09-27 2006-04-06 Kosan Biosciences Incorporated Specific kinase inhibitors
EA200700757A1 (ru) 2004-09-28 2007-10-26 Янссен Фармацевтика Н.В. Замещённые дипиперидиновые антагонисты ccr2
EP1802345A2 (en) 2004-10-01 2007-07-04 Medarex, Inc. Methods of treating cd30 positive lymphomas
RU2007121508A (ru) 2004-11-10 2008-12-20 Сги Фармасьютиклз Определенные имидазо[1, 2-а]пиразин-8-иламины, методы их получения и методы их применения
GB0425035D0 (en) 2004-11-12 2004-12-15 Novartis Ag Organic compounds
KR100735639B1 (ko) 2004-12-29 2007-07-04 한미약품 주식회사 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법
PL1848414T3 (pl) 2005-02-03 2011-10-31 Wyeth Llc Sposób leczenia nowotworu opornego na gefitinib
AU2006223409B2 (en) 2005-03-10 2011-07-21 Gilead Connecticut, Inc. Certain substituted amides, method of making, and method of use thereof
MX2007011767A (es) 2005-03-23 2007-10-18 Pfizer Prod Inc Terapia de combinacion de anticuerpo anti-ctla4 e indolinona para el tratamiento del cancer.
US7599542B2 (en) 2005-04-08 2009-10-06 John Philip Brockway System and method for detection and display of diseases and abnormalities using confidence imaging
DK1888550T3 (da) 2005-05-12 2014-09-29 Abbvie Bahamas Ltd Apoptosepromotorer
BRPI0610278A2 (pt) 2005-05-13 2010-06-08 Irm Llc compostos e composições como inibidores de proteìna cinase
WO2007002325A1 (en) 2005-06-22 2007-01-04 Plexxikon, Inc. Pyrrolo[2,3-b] pyridine derivatives as protein kinase inhibitors
PL1907424T3 (pl) 2005-07-01 2015-12-31 Squibb & Sons Llc Ludzkie monoklonalne przeciwciała wobec liganda zaprogramowanej śmierci 1 (PD-L1)
US20070065449A1 (en) 2005-09-16 2007-03-22 Claire Verschraegen Method of treating cancer, especially soft tissue sarcoma utilizing gemcitabine in combination with docetaxel and anti-VEGF therapy (bevacizumab)
JP5363107B2 (ja) 2005-11-04 2013-12-11 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル アジュバントを含むスプリットインフルエンザワクチンにおけるｔｈ１／ｔｈ２バランスの変化
CA2629314A1 (en) 2005-11-12 2007-05-24 Boehringer Ingelheim International Gmbh Tec kinase inhibitors
WO2007059329A2 (en) 2005-11-16 2007-05-24 Pharmacyclics, Inc. Methods and compositions for treating cancer
ES2398319T3 (es) 2005-12-28 2013-03-15 Vertex Pharmaceuticals Incorporated Derivados de 1-(benzo[D][1,3]dioxol-5-il)-N-(fenil)ciclopropano-carboxamida y compuestos relacionados como moduladores de transportadores de casetes de unión a ATP para el tratamiento de la fibrosis quística
KR20080098490A (ko) 2006-01-13 2008-11-10 파마시클릭스, 인코포레이티드 티로신 키나제 억제제 및 이의 용도
EP1984030B1 (en) * 2006-01-30 2013-05-08 The Scripps Research Institute Methods for detection of circulating tumor cells and methods of diagnosis of cancer in a mammalian subject
US7908091B2 (en) 2006-03-17 2011-03-15 Prometheus Laboratories Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
GB0605521D0 (en) 2006-03-18 2006-04-26 Isis Innovation Adjuvant
DK2004654T3 (da) 2006-04-04 2013-07-22 Univ California Pyrazolopyrimidin derivater til anvendelse som kinase antagonister
US20090098137A1 (en) 2006-04-05 2009-04-16 Novartis Ag Combinations of therapeutic agents for treating cancer
KR101292508B1 (ko) 2006-04-07 2013-08-01 노파르티스 아게 백혈병의 치료를 위한, 피리미딜아미노벤즈아미드 화합물과 조합된 ｃ-ｓｒｃ 억제제의 용도
EP2865381A1 (en) 2006-05-18 2015-04-29 Pharmacyclics, Inc. ITK inhibitors for treating blood cell malignancies
EP2054076A2 (en) 2006-08-21 2009-05-06 United Therapeutics Corporation Combination therapy for treatment of viral infections
CA2663116C (en) 2006-09-22 2014-06-10 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US20220213106A1 (en) 2006-09-22 2022-07-07 Pharmacyclics Llc Inhibitors of Bruton's Tyrosine Kinase
EP2862579B1 (en) 2006-10-04 2017-05-17 Dana-Farber Cancer Institute, Inc. Tumor immunity
CA2668286C (en) 2006-11-03 2014-09-16 Pharmacyclics, Inc. Bruton's tyrosine kinase activity probe and method of using
AU2007328427A1 (en) 2006-11-06 2008-06-12 Source Precision Medicine, Inc. Gene expression profiling for identification, monitoring and treatment of melanoma
KR20120090100A (ko) 2006-12-26 2012-08-16 파마시클릭스, 인코포레이티드 병용 치료에 있어서 히스톤 디아세틸라제 억제제 이용 및 생체표지 감시 방법
US8741849B2 (en) 2007-01-10 2014-06-03 Purdue Research Foundation Kinase inhibitors and uses thereof
AU2008216327A1 (en) 2007-02-15 2008-08-21 Novartis Ag Combination of LBH589 with other therapeutic agents for treating cancer
NL2000640C2 (nl) 2007-03-05 2008-09-08 Stichting Wetsus Ct Of Excelle Werkwijze en systeem voor het zuiveren van een vloeistof.
SI2134374T1 (sl) 2007-03-14 2014-03-31 Bionsil S.R.L. In Liquidazione Inhibitorji btk za rabo pri zdravljenju na kemoterapevtska zdravila rezistentnih epitelijskih tumorjev
EP2560007A1 (en) 2007-03-28 2013-02-20 Pharmacyclics, Inc. Identification of bruton's tyrosine kinase inhibitors
US20120065201A1 (en) 2007-03-28 2012-03-15 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US8809273B2 (en) 2007-03-28 2014-08-19 Pharmacyclics, Inc. Inhibitors of Bruton's tyrosine kinase
US20100088264A1 (en) 2007-04-05 2010-04-08 Aureon Laboratories Inc. Systems and methods for treating diagnosing and predicting the occurrence of a medical condition
US20090010911A1 (en) 2007-04-06 2009-01-08 Iowa State University Research Foundation, Inc. Methods and compositions for affecting cyclophilin a regulation of kinases in modulating cellular activities
WO2008127659A2 (en) 2007-04-13 2008-10-23 University Of Texas Southwestern Medical Center Combination therapy for cancer
PE20090422A1 (es) 2007-04-27 2009-04-18 Purdue Pharma Lp Derivados de piperidina, piperazina o tetrahidropiridilo como antagonistas de trpv1
WO2008138578A2 (en) 2007-05-11 2008-11-20 Medical Prognosis Institute Methods, kits, and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
JP5376780B2 (ja) 2007-08-08 2013-12-25 株式会社東芝 圧電モータおよびカメラ装置
US7989465B2 (en) 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
AU2008314632B2 (en) 2007-10-19 2015-05-28 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
CA2701275C (en) 2007-10-23 2016-06-21 F. Hoffmann-La Roche Ag Kinase inhibitors
NZ585500A (en) 2007-11-12 2012-06-29 Theraclone Sciences Inc Antibodies which bind to an epitope in the extracellular domain of the matrix 2 ectodomain polypeptide of an influenza virus
US8426441B2 (en) 2007-12-14 2013-04-23 Roche Palo Alto Llc Inhibitors of bruton's tyrosine kinase
US20150152115A1 (en) 2007-12-27 2015-06-04 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
CN101475632B (zh) 2008-01-03 2012-01-04 张喜田 具有抗肿瘤作用的重组灵芝免疫调节蛋白及其药物制剂
WO2009089399A2 (en) 2008-01-10 2009-07-16 Bausch & Lomb Incorporated Compositions comprising toll-like receptor or coreceptor antagonists and methods for ocular neuroprotection
GB0805356D0 (en) 2008-03-25 2008-04-30 Isis Innovation Vaccine adjuvant composition
CA2716884C (en) 2008-03-25 2017-10-03 Charles Dumontet Use of a type ii anti-cd20 antibody with increased antibody dependent cellular cytotoxicity (adcc) in combination with cyclophosphamide, vincristine and doxorubicine for treating non-hodgkin's lymphomas
CN102036658A (zh) 2008-05-23 2011-04-27 香港大学 治疗流感的联合疗法
US20110218512A1 (en) 2008-06-03 2011-09-08 Aethlon Medical, Inc. Enhanced antiviral therapy methods and devices
CA3031835C (en) 2008-06-27 2021-09-07 Celgene Car Llc Heteroaryl compounds and uses thereof
CN102159214A (zh) 2008-07-16 2011-08-17 药品循环公司 用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂
MX2011001005A (es) 2008-07-29 2011-09-01 Frontier Scient Inc Uso de derivados de tetraquis (n-alquilpiridinio)-porfirina para eliminacion de microbios o prevencion del crecimiento.
BRPI0918970A2 (pt) 2008-09-05 2019-09-24 Avila Therapeutics Inc algoritmo para projeto de inibidores irreversíveis
WO2010034670A2 (en) 2008-09-26 2010-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Host cell kinases as targets for antiviral therapies against hcv infection
CN102271683B (zh) 2008-11-13 2014-07-09 吉里德卡利斯托加公司 恶性血液病的治疗
UA108193C2 (uk) 2008-12-04 2015-04-10 Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8426428B2 (en) 2008-12-05 2013-04-23 Principia Biopharma, Inc. EGFR kinase knockdown via electrophilically enhanced inhibitors
RU2017132160A (ru) 2008-12-09 2019-02-08 Дженентек, Инк. Антитела к pd-l1 и их применение для усиления функции t-клеток
EA026557B1 (ru) 2008-12-09 2017-04-28 Джилид Сайэнс, Инк. Промежуточные соединения для получения модуляторов толл-подобных рецепторов
JP2012512157A (ja) 2008-12-15 2012-05-31 イーライ リリー アンド カンパニー 癌を治療するためのエンザスタウリン
WO2010069809A1 (en) 2008-12-18 2010-06-24 F. Hoffmann-La Roche Ag Biomarkers for hcv treatment response
EP2396028A2 (en) 2009-02-12 2011-12-21 Vertex Pharmceuticals Incorporated Hcv combination therapies comprising pegylated interferon, ribavirin and telaprevir
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
BRPI1006438A2 (pt) 2009-04-20 2016-09-27 Genentech Inc terapia adjuvante de cancer
JP5656976B2 (ja) 2009-04-29 2015-01-21 ローカス ファーマシューティカルズ インコーポレイテッド ピロロトリアジン化合物
CN104906100A (zh) 2009-05-26 2015-09-16 艾伯维巴哈马有限公司 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂
LU91583B1 (en) 2009-07-03 2011-01-04 Wurth Paul Sa Sealing valve arrangement for a shaft furnace charging installation
NZ598705A (en) 2009-09-16 2014-06-27 Celgene Avilomics Res Inc Protein kinase conjugates and inhibitors
GB2474748B (en) 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
US7718662B1 (en) 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
BR112012008849A2 (pt) 2009-10-14 2015-09-22 Schering Corp composto, composição farmacêutica, e, uso de um composto
US8299070B2 (en) 2009-11-25 2012-10-30 Japan Tobacco Inc. Indole compounds and pharmaceutical use thereof
ES2629170T3 (es) 2009-12-04 2017-08-07 Senhwa Biosciences, Inc. Pirazolopirimidinas y heterociclos relacionados como inhibidores de CK2
WO2011133609A2 (en) 2010-04-19 2011-10-27 The Translational Genomics Research Institute Methods and kits to predict therapeutic outcome of btk inhibitors
EA201690998A1 (ru) 2010-05-17 2017-01-30 Инкозен Терапьютикс Пвт. Лтд. НОВЫЕ СОЕДИНЕНИЯ 3,5-ДИЗАМЕЩЕННОГО-3H-ИМИДАЗО[4,5-b]ПИРИДИНА И 3,5-ДИЗАМЕЩЕННОГО-3H-[1,2,3]ТРИАЗОЛО[4,5-b]ПИРИДИНА КАК МОДУЛЯТОРЫ ПРОТЕИНКИНАЗ
CA2799944A1 (en) 2010-05-20 2011-11-24 University Of Rochester Methods and compositions related to modulating autophagy
PL2578585T3 (pl) 2010-05-31 2017-01-31 Ono Pharmaceutical Co., Ltd. Pochodna purynonu jako inhibitor kinazy btk
MX342405B (es) 2010-06-03 2016-09-28 Pharmacyclics Inc El uso de inhibidores de la tirosina quinasa de bruton (btk).
US20120071497A1 (en) 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
PT2975042T (pt) 2010-06-23 2019-01-11 Hanmi Science Co Ltd Novos derivados de pirimidina fundidos para inibição de atividade de tirosina-quinase
WO2011160206A1 (en) 2010-06-23 2011-12-29 Morin Ryan D Biomarkers for non-hodgkin lymphomas and uses thereof
GB2481611A (en) 2010-06-30 2012-01-04 Statoil Asa Test cell for well fluid assessment
CN105566229A (zh) 2010-08-10 2016-05-11 西建阿维拉米斯研究公司 Btk抑制剂的苯磺酸盐及其用途和制备方法
UA119150C2 (uk) 2010-11-23 2019-05-10 Еббві Айрленд Анлімітед Компані СПОСОБИ ЛІКУВАННЯ З ВИКОРИСТАННЯМ СЕЛЕКТИВНИХ ІНГІБІТОРІВ Всl-2
JP5707518B2 (ja) 2011-02-28 2015-04-30 カリトル サイエンシズ， エルエルシー 置換型キノリン化合物及び使用方法
AU2012255860C1 (en) 2011-05-17 2015-12-10 Principia Biopharma Inc. Tyrosine kinase inhibitors
CN103765212A (zh) 2011-06-27 2014-04-30 杰克逊实验室 治疗癌症和自体免疫性疾病的方法和组合物
HK1198475A1 (en) 2011-07-19 2015-05-08 无限药品股份有限公司 Heterocyclic compounds and uses thereof
RS58177B1 (sr) 2011-07-19 2019-03-29 Merck Sharp & Dohme 4-imidazopiridazin-1-il-benzamidi i 4-imidazotriazin-1-il-benzamidi kao inhibitori btk
WO2013036994A1 (en) 2011-09-16 2013-03-21 Biota Scientific Management Pty Ltd Compounds for the treatment of hcv
US8580958B1 (en) 2011-09-22 2013-11-12 The United States Of America As Represented By The Secretary Of The Air Force Two-photon absorbing polyhydroxy diphenylamino-dialkylfluorene-1,3,5-triazine molecules
KR20230109775A (ko) 2011-10-19 2023-07-20 파마싸이클릭스 엘엘씨 브루톤 티로신 인산화효소(btk)의 억제제의 용도
CN104203937A (zh) 2011-11-03 2014-12-10 霍夫曼-拉罗奇有限公司 作为btk活性的抑制剂的8-氟酞嗪-1(2h)-酮化合物
US9192664B2 (en) 2011-12-05 2015-11-24 Immunomedics, Inc. Therapeutic use of anti-CD22 antibodies for inducing trogocytosis
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
CN104582705A (zh) 2012-01-10 2015-04-29 林伯士艾瑞斯公司 白介素-1受体相关激酶(irak)抑制剂和其用途
US8501724B1 (en) 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
US20150072988A1 (en) 2012-03-30 2015-03-12 The Johns Hopkins University Use of n-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine in combination with histone deacetylase inhibitors for treatment of cancer
GB201207305D0 (en) 2012-04-26 2012-06-13 E Therapeutics Plc Therapy
JP5514256B2 (ja) 2012-05-18 2014-06-04 株式会社東芝 磁気記憶素子及びその製造方法
TWI662964B (zh) 2012-06-04 2019-06-21 美商製藥有限責任公司 布魯頓氏酪胺酸激酶抑制劑之結晶形式
SG10201805807PA (en) 2012-06-26 2018-08-30 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
WO2014004707A1 (en) 2012-06-29 2014-01-03 Principia Biopharma Inc. Formulations comprising ibrutinib
EP2872134A4 (en) 2012-07-10 2016-01-27 Univ California PROCESS FOR INDUCING ANESTHESIA
US8684552B2 (en) 2012-07-11 2014-04-01 Agio International Company, Ltd Lighted furniture assembly
CN104704129A (zh) 2012-07-24 2015-06-10 药品循环公司 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变
US9539251B2 (en) 2012-09-07 2017-01-10 Genentech, Inc. Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor
US9944991B2 (en) 2012-11-02 2018-04-17 Dana-Farber Cancer Institute, Inc. Compositions and methods for diagnosis, prognosis and treatment of hematological malignancies
BR112015010059A2 (pt) 2012-11-02 2017-07-11 Pharmacyclics Inc terapia adjuvante com inibidor da quinase da família tec
CN104854107A (zh) 2012-11-15 2015-08-19 药品循环公司 作为激酶抑制剂的吡咯并嘧啶化合物
HK1216859A1 (zh) 2013-01-10 2016-12-09 Nimbus Iris, Inc. Irak抑制劑和其用途
US9481682B2 (en) 2013-01-23 2016-11-01 Merck Sharp & Dohme Corp. Substituted benzamides and substituted pyridinecarboxamides as Btk inhibitors
EP2953645A4 (en) 2013-02-07 2016-12-28 Immunomedics Inc PRO-MEDICINE FORM (P2PDOX) OF HIGHLY POWERFUL 2-PYRROLINODOXORUBICIN CONJUGATED TO ANTIBODIES FOR TARGETED CANCER THERAPY
FR3002733B1 (fr) 2013-03-04 2015-08-14 Servier Lab Nouveau sel de l'abexinostat, forme cristalline associee,leur procede de preparation et les compositions pharmaceutiques qui les contiennent
ES2662598T3 (es) 2013-03-08 2018-04-09 F. Hoffmann-La Roche Ag Análisis de sangre para la detección de mutaciones de EGFR
CN105073115A (zh) 2013-03-14 2015-11-18 药品循环有限责任公司 布鲁顿氏酪氨酸激酶抑制剂和cyp3a4抑制剂的组合
HK1215374A1 (zh) 2013-04-08 2016-08-26 Pharmacyclics Llc 依鲁替尼联合疗法
SG11201509842SA (en) 2013-05-30 2015-12-30 Infinity Pharmaceuticals Inc Treatment of cancers using pi3 kinase isoform modulators
LT3004106T (lt) 2013-06-07 2018-02-26 Rhizen Pharmaceuticals S.A. Dvigubi selektyvūs p13 delta ir gamma kinazės inhibitoriai
CN105764501A (zh) 2013-07-26 2016-07-13 现代化制药公司 改善比生群治疗效益的组合物
TWI649081B (zh) 2013-08-02 2019-02-01 製藥公司 治療固態腫瘤之方法
WO2015018522A1 (en) 2013-08-06 2015-02-12 Oncoethix Sa Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl)
EP3033079B1 (en) 2013-08-12 2018-10-31 Pharmacyclics LLC Methods for the treatment of her2 amplified cancer
CA2925124A1 (en) 2013-09-30 2015-04-02 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
WO2015054197A1 (en) 2013-10-10 2015-04-16 Acetylon Pharmaceuticals, Inc. Hdac inhibitors, alone or in combination with btk inhibitors, for treating non-hodgkin's lymphoma
TWI660739B (zh) 2013-10-25 2019-06-01 製藥公司 使用布魯頓氏酪胺酸激酶抑制劑之治療及免疫療法
US9795604B2 (en) 2013-10-25 2017-10-24 Pharmacyclics Llc Methods of treating and preventing graft versus host disease
KR20160084438A (ko) 2013-11-13 2016-07-13 노파르티스 아게 면역 반응을 강화하기 위한 mTOR 억제제
US10314842B2 (en) 2013-12-02 2019-06-11 Cornell University Methods for treating B cell proliferative disorders
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
CN105949197A (zh) 2014-01-29 2016-09-21 苏州晶云药物科技有限公司 依鲁替尼的新晶型及其制备方法
WO2015127234A1 (en) 2014-02-20 2015-08-27 Board Of Regents, The University Of Texas System Use of ibrutinib to treat egfr mutant cancer
WO2015127261A1 (en) 2014-02-21 2015-08-27 Pharmacyclics, Inc. Biomarkers for predicting response of dlbcl to treatment with ibrutinib
JP2017509336A (ja) 2014-03-20 2017-04-06 ファーマサイクリックス エルエルシー ホスホリパーゼｃガンマ２及び耐性に関連した変異
NZ724796A (en) 2014-04-04 2019-04-26 Bionomics Ltd Method for treating chronic lymphocytic leukemia
US9815842B2 (en) 2014-05-28 2017-11-14 Novartis Ag Pyrazolo pyrimidine derivatives and their use as MALT1 inhibitors
US20150361504A1 (en) 2014-06-13 2015-12-17 Pharmacyclics Llc Biomarker for predicting response of cll to treatment with a btk inhibitor
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016014859A1 (en) 2014-07-25 2016-01-28 Pharmacyclics Llc Bet inhibitor and bruton's tyrosine kinase inhibitor combinations
JP2017523188A (ja) 2014-08-01 2017-08-17 ファーマサイクリックス エルエルシー Ｂｔｋ阻害剤を伴う治療に対するｄｌｂｃｌの応答を予測するためのバイオマーカー
SG11201700849XA (en) 2014-08-07 2017-03-30 Pharmacyclics Llc Novel formulations of a bruton's tyrosine kinase inhibitor
AU2015300966A1 (en) 2014-08-08 2017-02-16 Janssen Pharmaceutica Nv Bruton's tyrosine kinase inhibitor combinations and uses thereof
US20170231995A1 (en) 2014-08-11 2017-08-17 Acerta Pharma B.V. BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment
PT3194401T (pt) 2014-09-16 2020-12-23 Gilead Sciences Inc Formas sólidas de modulador de recetor tipo toll
WO2016044774A1 (en) 2014-09-18 2016-03-24 Pharmacyclics Llc Dendritic cell based vaccine with bruton's tyrosine kinase inhibitor
BR112017006664A2 (pt) 2014-10-03 2017-12-26 Novartis Ag terapias de combinação
WO2016054627A1 (en) 2014-10-03 2016-04-07 Ohio State Innovation Foundation Biomarkers of bruton tyrosine kinase inhibitor resistance
EP4029508A1 (en) 2014-10-10 2022-07-20 Idera Pharmaceuticals, Inc. Treatment of cancer using tlr9 agonists and checkpoint inhibitors
KR102513870B1 (ko) 2014-10-14 2023-03-23 노파르티스 아게 Pd-l1에 대한 항체 분자 및 그의 용도
TW201628622A (zh) 2014-11-17 2016-08-16 製藥公司 Tlr抑制劑與布魯頓氏(bruton's)酪胺酸激酶抑制劑之組合
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
EP3236968A4 (en) 2014-12-23 2018-08-01 Pharmacyclics LLC Btk inhibitor combinations and dosing regimen
WO2016123504A1 (en) 2015-01-30 2016-08-04 Pharmacyclics Llc Btk inhibitor combinations and multidrug-resistance
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
RS56787B1 (sr) 2015-03-04 2018-04-30 Gilead Sciences Inc Toll-like receptor koji modulira jedinjenja 4,6-diamino-pirido[3,2-d]pirimidina
WO2016161347A1 (en) 2015-04-03 2016-10-06 Pharmacyclics Llc Combinations for generating tumor-specific immunological memory
CN106336413B (zh) 2015-07-09 2021-04-20 广东东阳光药业有限公司 作为jak抑制剂的化合物及其用途
WO2017011314A1 (en) 2015-07-10 2017-01-19 Paharmacyclics Llc Btk and hdac combinations
CN106474143A (zh) 2015-08-26 2017-03-08 长春华普生物技术有限公司 Toll样受体TLR7和TLR9抑制性寡核苷酸在制备用于治疗B细胞淋巴瘤的药物方面的应用
MX2018002554A (es) 2015-08-31 2018-08-14 Pharmacyclics Llc Combinaciones de inhibidores de btk para tratar mieloma multiple.
US20170071962A1 (en) 2015-09-11 2017-03-16 Acerta Pharma B.V. Therapeutic Combinations of a Proteasome Inhibitor and a BTK Inhibitor
WO2017087947A2 (en) 2015-11-19 2017-05-26 Pharmacyclics Llc Method of treatment of follicular lymphoma with a btk inhibitor

Also Published As

Publication number Publication date
JP2013527249A (ja) 2013-06-27
EP2575818A2 (en) 2013-04-10
MX380899B (es) 2025-03-12
NZ755485A (en) 2021-04-30
MY191929A (en) 2022-07-18
JP6057309B2 (ja) 2017-01-11
JP6376416B2 (ja) 2018-08-22
CA3113343C (en) 2024-10-08
PH12021550758A1 (en) 2022-02-21
JP2018197238A (ja) 2018-12-13
MX342405B (es) 2016-09-28
SG10201809111XA (en) 2018-11-29
WO2011153514A2 (en) 2011-12-08
US20190358234A1 (en) 2019-11-28
JP2022088408A (ja) 2022-06-14
US20130310402A1 (en) 2013-11-21
US9801881B2 (en) 2017-10-31
NZ717373A (en) 2017-11-24
MX380504B (es) 2025-03-12
US8999999B2 (en) 2015-04-07
IL300955A (en) 2023-04-01
CA3007787A1 (en) 2011-12-08
KR101580714B1 (ko) 2016-01-04
CA3113343A1 (en) 2011-12-08
MX2012014049A (es) 2013-03-12
BR112012030625A2 (pt) 2017-06-27
US20180036313A1 (en) 2018-02-08
US20220175785A1 (en) 2022-06-09
CA3007788C (en) 2020-03-10
US10004746B2 (en) 2018-06-26
US10004745B2 (en) 2018-06-26
CN107898791A (zh) 2018-04-13
CA3022256A1 (en) 2011-12-08
CA3007788A1 (en) 2011-12-08
WO2011153514A9 (en) 2012-04-05
US20230293532A1 (en) 2023-09-21
US11672803B2 (en) 2023-06-13
US10016435B2 (en) 2018-07-10
US20150031710A1 (en) 2015-01-29
EA201270793A2 (ru) 2013-08-30
MX2020004438A (es) 2021-03-25
PH12016501206A1 (en) 2018-02-12
SG186077A1 (en) 2013-01-30
US20220249494A1 (en) 2022-08-11
IL275459A (en) 2020-08-31
US20130273030A1 (en) 2013-10-17
US10478439B2 (en) 2019-11-19
US10751342B2 (en) 2020-08-25
US20120100138A1 (en) 2012-04-26
EP2575818A4 (en) 2013-11-06
US8754090B2 (en) 2014-06-17
CA2800913A1 (en) 2011-12-08
IL223181A0 (en) 2013-02-03
CA2800913C (en) 2019-07-23
US20140194446A1 (en) 2014-07-10
US20160324859A1 (en) 2016-11-10
CA3154024C (en) 2024-02-27
US20130202611A1 (en) 2013-08-08
CN103153311A (zh) 2013-06-12
JP2024028806A (ja) 2024-03-05
PH12012502356A1 (en) 2013-02-11
KR20130086957A (ko) 2013-08-05
US20170035762A1 (en) 2017-02-09
US20120087915A1 (en) 2012-04-12
US20180280395A1 (en) 2018-10-04
US9814721B2 (en) 2017-11-14
MX387728B (es) 2025-03-18
MX2020004501A (es) 2021-11-09
EA201270793A8 (ru) 2019-01-31
CA3240281A1 (en) 2011-12-08
US20130195852A1 (en) 2013-08-01
EA201890869A3 (ru) 2019-03-29
US20150031711A1 (en) 2015-01-29
US20200163968A1 (en) 2020-05-28
PH12016501206B1 (en) 2018-02-12
US10653696B2 (en) 2020-05-19
JP5841998B2 (ja) 2016-01-13
JP6580760B2 (ja) 2019-09-25
JP2017039767A (ja) 2017-02-23
US20230248730A1 (en) 2023-08-10
NZ753024A (en) 2020-08-28
IL223181B (en) 2020-10-29
US9801883B2 (en) 2017-10-31
US20210169885A1 (en) 2021-06-10
CA3007787C (en) 2020-03-10
CA3154024A1 (en) 2011-12-08
US9125889B2 (en) 2015-09-08
EA031737B1 (ru) 2019-02-28
AU2011261185A1 (en) 2013-01-10
JP2021155426A (ja) 2021-10-07
ZA201209381B (en) 2014-05-28
CA3022256C (en) 2021-03-30
JP2016065078A (ja) 2016-04-28
NZ789041A (en) 2023-09-29
US20120183535A1 (en) 2012-07-19
US20180256581A1 (en) 2018-09-13
NZ702485A (en) 2016-04-29
JP2020063231A (ja) 2020-04-23
JP7042950B2 (ja) 2022-03-28
US20180015091A1 (en) 2018-01-18
EA201890869A2 (ru) 2018-09-28
NZ736048A (en) 2019-09-27
US20160175312A1 (en) 2016-06-23
NZ772688A (en) 2022-09-30
CL2012003381A1 (es) 2013-03-22

Similar Documents

Publication Publication Date Title
NZ604040A (en) The use of inhibitors of bruton’s tyrosine kinase (btk)
WO2009008992A3 (en) Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mt0rc2
PH12020500028A1 (en) Crystalline forms of a bruton`s tyrosine kinase inhibitor
AR094654A1 (es) Modulador del receptor de andrógeno y sus usos, método para tratamiento, composición farmacéutica
Fleurence et al. A systematic review of augmentation strategies for patients with major depressive disorder
JP2017523207A5 (enExample)
NZ599439A (en) Compositions and methods for treating centrally mediated nausea and vomiting
MX2009003372A (es) Formas de dosificacion de pelicula no mucoadhesiva.
JP2017503842A5 (enExample)
EP4338738A3 (en) Pharmaceutical formulations of a bruton's tyrosine kinase inhibtor
NZ707377A (en) Combination therapy methods for treating proliferative diseases
UY32177A (es) Tratamiento de diabetes en pacientes con control glucémico insuficiente a pesar de la terapia con fármaco, oral o no, antidiabético
PA8855101A1 (es) Formulaciones de imiquimod de menor potencia de dosificación y regímenes de dosificación cortos para tratar queratosis actínica
BR112012008345A2 (pt) regime de dosagem para a administração de um anticorpo biespecífico de epcamxcd3
AR087356A1 (es) Terapia de combinacion para el tratamiento de sintomas de tumores malignos de celulas b cd19que comprende inmunoconjugado maitansinoide anti-cd19 y rituximab
BR112012000862A2 (pt) composição farmaceutica oral, composição farmaceutica oral de baixa dose para administração cronica de tratamento de retardo do inicio ou desenvolvimento de uma condição metodo de tratamento da dor em um individuo que necessita deste medicamento, metodo de tratamento de uma condição em um individuo que necessita deste medicamento
AR090885A1 (es) Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple
WO2013071056A3 (en) Combination drug therapy for the treatment of solid tumors
Blackhall et al. Improving survival and reducing toxicity with chemotherapy in advanced non-small cell lung cancer: a realistic goal?
MX2009003532A (es) Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina.
US10857124B2 (en) Multivitamin capable of beneficial gene regulation through microRNA (MIRNA)
Sailo et al. Molecular alterations involved in pancreatic cancer chemoresistance and chemosensitization strategies
Learn et al. Randomized clinical trials in gastrointestinal stromal tumors
NZ803183A (en) The use of inhibitors of Bruton's tyrosine kinase (Btk)
NZ803183B2 (en) The use of inhibitors of Bruton's tyrosine kinase (Btk)

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 JUN 2016 BY CPA GLOBAL

Effective date: 20150710

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 JUN 2017 BY THOMSON REUTERS

Effective date: 20160512

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 JUN 2018 BY THOMSON REUTERS

Effective date: 20170527

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 JUN 2019 BY THOMSON REUTERS

Effective date: 20180509

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 JUN 2020 BY THOMSON REUTERS

Effective date: 20190516

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 JUN 2021 BY THOMSON REUTERS

Effective date: 20200517

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 JUN 2022 BY THOMSON REUTERS

Effective date: 20210505

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 JUN 2023 BY THOMSON REUTERS

Effective date: 20220503

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 JUN 2024 BY THOMSON REUTERS

Effective date: 20230501

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 JUN 2025 BY THOMSON REUTERS

Effective date: 20240502

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 03 JUN 2026 BY THOMSON REUTERS

Effective date: 20250501